Industry News & Literature
Stay ahead with expert-curated flow cytometry & cell/gene therapy news, landmark publications (including OMICs),
and fresh open-access research — all centralized to save you hours every week.
Featured Industry News
Handpicked headlines in flow cytometry & cell/gene therapy. Non-members see a preview; members get the full feed.
March 9, 2026 – Flow Cytometry
Cytek Biosciences Strengthens Global Manufacturing and Support Infrastructure
• Singapore facility supports Cytek’s global manufacturing and logistics network
• Regional hub for customer training, technical support, and service
• Expansion reflects increasing demand for spectral cytometry technologies
• Strengthens supply-chain resilience and regional instrument support
Source: https://www.globenewswire.com/news-release/2026/03/09/3252344/0/en/Cytek-Biosciences-Celebrates-One-Year-of-Operations-at-Singapore-Facility-Accelerating-Growth-and-Regional-Impact.html
March 10, 2026 – Flow Cytometry
Flow Cytometry Enters the Lung Cancer Diagnostic Landscape
•Large multicenter study evaluating a sputum-based cytometry diagnostic
• Target enrollment of approximately 2,000 patients
• Technology aims to provide non-invasive lung cancer risk assessment
• Represents expansion of flow cytometry into clinical diagnostics
Source: https://www.biospace.com/press-releases/bioaffinity-technologies-announces-initiation-of-large-scale-longitudinal-clinical-study-for-its-noninvasive-cypath-lung-cancer-diagnostic
March 31, 2026 – Flow Cytometry
New Flow Cytometry Method for T-Cell Clonality Detection
• Dual detection of cyTRBC1 and cyTRBC2 enables clonality assessment
• Potential alternative or complement to molecular clonality testing
• Integrates into standard diagnostic flow cytometry panels
• Could improve rapid screening for T-cell malignancies
Source: https://www.nature.com/articles/s41408-026-01483-1
March 27, 2026 – CGT
FDA Approves First Gene Therapy for Leukocyte Adhesion Deficiency-I
• First FDA-approved therapy specifically targeting severe LAD-I
• Demonstrates continued regulatory progress for autologous gene-corrected stem cell
therapies
• Highlights expanding gene therapy applications for rare pediatric diseases
• Commercial launch expected through specialized treatment centers beginning in 2026
Source: https://www.globenewswire.com/news-release/2026/03/09/3252344/0/en/Cytek-Biosciences-Celebrates-One-Year-of-Operations-at-Singapore-Facility-Accelerating-Growth-and-Regional-Impact.html
March 19, 2026 – CGT
AstraZeneca Expands Global Cell Therapy Manufacturing in China
• AstraZeneca expanding cell therapy manufacturing footprint in Asia
• New Shanghai facility designed for end-to-end CAR-T development and production
• Reflects rapid growth of China’s cell therapy ecosystem
• Manufacturing infrastructure remains a key strategic investment for CGT commercialization
Source: https://www.biospace.com/press-releases/bioaffinity-technologies-announces-initiation-of-large-scale-longitudinalclinical-
study-for-its-noninvasive-cypath-lung-cancer-diagnostic
March 11, 2026 – CGT
Phase 3 Data for Deramiocel Cell Therapy Presented at MDA 2026
• Phase 3 HOPE-3 results presented at the 2026 MDA scientific conference
• Deramiocel targets Duchenne muscular dystrophy-associated cardiomyopathy
• Therapy consists of allogeneic cardiosphere-derived cells
• Clinical study report submitted to FDA as part of ongoing BLA review
Source: https://www.nature.com/articles/s41408-026-01483-1
Curated Literature Highlights
2020-07-15 – Cytometry Part A
OMIP-069: 40-Color Full-Spectrum Flow Cytometry Panel for Deep Immunophenotyping of Major Cell Subsets of the Human Peripheral Blood
What it is: A community-adopted, 40-color spectral panel and workflow that unlocked routine, high-parameter immunophenotyping on full-spectrum instruments.
Why landmark (metrics): Cited well over 100 times (PubMed shows “Cited by” >300); method has become a go-to reference for building large spectral panels across core facilities.
2021-12-02 – Blood
2021 Update on MRD in Acute Myeloid Leukemia: A Consensus Document From the European LeukemiaNet MRD Working Party
What it is: The global standard-setting MRD guideline integrating flow cytometry (and molecular) with thresholds, time points, and reporting rules used in trials and clinical care.
Why landmark (metrics): Cited >600 times and directly drives assay design/interpretation and clinical decisions worldwide; widely implemented by hospital and reference labs.
2021-09-20 – Cytometry Part A
Full Spectrum Flow Cytometry as a Powerful Technology for Cancer Immunotherapy Research
What it is: A practice-oriented review that codified best practices for spectral instrumentation, panel design, unmixing, and analysis in immuno-oncology.
Why landmark (metrics): Cited ~110 times; catalyzed rapid adoption of spectral cytometry across IO programs and cores by providing a clear, implementable playbook.
How SuperNova Flow Cytometry Saves You Time
No more endless PubMed searches or scattered Google alerts —
our curated hub saves hours every week, so you can focus on discovery and innovation.
Save Hours
Members cut down research time by accessing centralized news and peer-reviewed literature.
Stay Focused
Skip irrelevant updates — our expert curation highlights only what impacts your work.
.
Trusted Sources
Every article comes from leading journals, conferences, and open-access databases.
.
Your Competitive Edge in Flow Cytometry & CGT
Join SuperNova Flow Cytometry to access curated industry news, landmark publications, and member-only resources —
all designed to save you time and keep you ahead of the curve.
ASCP- and ASC-accredited CMLE credits included with every accredited-course.